TriSalus Life Sciences, Inc.TLSIWEarnings & Financial Report
Nasdaq
TLSIW Q3 2025 Key Financial Metrics
Revenue
$11.6M
Gross Profit
$9.7M
Operating Profit
$-9.0M
Net Profit
$-10.8M
Gross Margin
83.5%
Operating Margin
-77.9%
Net Margin
-93.5%
YoY Growth
57.4%
EPS
$-0.96
Financial Flow
TriSalus Life Sciences, Inc. Q3 2025 Financial Summary
TriSalus Life Sciences, Inc. reported revenue of $11.6M for Q3 2025, with a net profit of $-10.8M (-93.5% margin). Cost of goods sold was $1.9M, operating expenses totaled $18.7M.
Key Financial Metrics
| Total Revenue | $11.6M |
|---|---|
| Net Profit | $-10.8M |
| Gross Margin | 83.5% |
| Operating Margin | -77.9% |
| Report Period | Q3 2025 |
TriSalus Life Sciences, Inc. Annual Revenue by Year
TriSalus Life Sciences, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $29.4M).
| Year | Annual Revenue |
|---|---|
| 2024 | $29.4M |
| 2023 | $18.5M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.7M | $6.5M | $7.4M | $7.3M | $8.3M | $9.2M | $11.2M | $11.6M |
| YoY Growth | N/A | 116.4% | 59.7% | 41.5% | 44.4% | 42.0% | 52.3% | 57.4% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $25.7M | $17.9M | $32.4M | $27.5M | $24.0M | $28.6M | $41.3M | $36.5M |
| Liabilities | $51.7M | $52.8M | $56.6M | $47.9M | $49.9M | $63.0M | $60.7M | $63.2M |
| Equity | $-25.9M | $-34.9M | $-24.1M | $-20.4M | $-25.9M | $-34.4M | $-19.4M | $-26.7M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-8.8M | $-10.9M | $-13.4M | $-10.8M | $-5.7M | $-4.5M | $-7.3M | $-3.7M |